

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Robin K. Kelley, Patrick Mollon, Jean-Frédéric Blanc, Bruno Daniele,
Thomas Yau, Ann-Lii Cheng, Velichka Valcheva, Florence Marteau,
Ines Guerra, Ghassan K. Abou-Alfa

Slide deck





Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Original Research article

Robin K. Kelley, Patrick Mollon, Jean-Frédéric Blanc, Bruno Daniele, Thomas Yau, Ann-Lii Cheng, Velichka Valcheva, Florence Marteau, Ines Guerra, Ghassan K. Abou-Alfa

Funding: This analysis was sponsored by Ipsen and the CELESTIAL study was funded by Exelixis. For a full list of declarations, including funding and author disclosure statements, please see the full text online.

This animation has been developed to accompany the Advances in Therapy article “Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma” and is not intended for any other use

Advances in Therapy (2020)

© The Authors, 2020 CC-BY-NC



Hepatocellular
carcinoma
(HCC)

Matching Adjusted Indirect Comparison



Indirect comparisons can inform decision making



No direct drug–drug comparisons in 2L HCC

Cabozantinib vs Placebo¹



Regorafenib vs Placebo²




Cabozantinib vs Regorafenib



1. Abou-Alfa GK et al. *N Eng J Med* 2018;379:54–63

2. Bruix J et al. *Lancet* 2017;389:56–66

Indirect comparison eligibility: differences



1. Abou-Alfa GK et al. *N Eng J Med* 2018;379:54–63

2. Bruix J et al. *Lancet* 2017;389:56–66

HCC, hepatocellular carcinoma; RCT, randomized controlled trial

2L trial populations

CELESTIAL¹

Cabozantinib (2L + 3L)


N = 707



RESORCE²

Regorafenib (2L)

N = 573



1. Abou-Alfa GK et al. N Eng J Med 2018;379:54–63

2. Bruix J et al. Lancet 2017;389:56–66


2L, second-line; 3L, third-line

2L trial populations

CELESTIAL¹

Cabozantinib (2L + 3L)

N = 707




2L patients: n = 495

RESORCE²

Regorafenib (2L)

N = 573




1. Abou-Alfa GK et al. N Eng J Med 2018;379:54–63

2. Bruix J et al. Lancet 2017;389:56–66

2L, second-line; 3L, third-line

Differences in effect-modifying characteristics

CELESTIAL¹
Baseline individual patient data



RESORCE²
Baseline population data



Similarity with RESORCE

Low

High

Ethnic mix

Geographical origin

ECOG performance status

Duration of prior sorafenib treatment


1. Abou-Alfa GK et al. N Eng J Med 2018;379:54–63

2. Bruix J et al. Lancet 2017;389:56–66

ECOG, Eastern Cooperative Oncology Group

Differences in effect-modifying characteristics

CELESTIAL¹
Baseline individual patient data



RESORCE²
Baseline population data



Similarity with RESORCE

Low

High

Standard indirect comparison



Matching-adjusted indirect comparison




1. Abou-Alfa GK et al. N Eng J Med 2018;379:54–63

2. Bruix J et al. Lancet 2017;389:56–66

Adjusting: individual patient data to population statistics

CELESTIAL¹
Baseline individual
patient data



Weight individual
baseline data of
matched patients



Matching-adjusted
2L population

1. Abou-Alfa GK et al. N Eng J Med 2018;379:54–63

2L, second-line


No significant differences in effect-modifying characteristics

CELESTIAL¹



Effective sample size: 266

RESORCE²




n = 573

1. Abou-Alfa GK et al. N Eng J Med 2018;379:54–63

2. Bruix J et al. Lancet 2017;389:56–66

2L, second-line

Evidence hierarchy



C, cabozantinib; R, regorafenib

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

A Video Abstract

10.1007/s12325-020-01378-y

